British drugmaker GlaxoSmithKline says its Covid-19 antibody drug appears to be effective against the Omicron variant, based on initial laboratory testing
Laboratory analysis of the antibody-based Covid-19 therapy that GlaxoSmithKline is developing with US partner Vir has indicated the drug is effective against the new Omicron variant, the British drugmaker has said.
An analysis of past tests has now yielded the preliminary clearance for the drug because Omicron's main mutations have been found across a variety of previous variants. The antibody is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein.Importantly, the mutations within the area on the spike protein that the sotrovimab antibodies bind to did not make a difference.
Separately, Britain's drug regulator on Thursday approved sotrovimab, also known under the brand name Xevudy, for people with mild to moderate Covid-19 and who are at high risk of developing severe disease.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
GSK says tests indicate antibody drug works against OmicronLaboratory analysis of the antibody-based COVID-19 therapy GlaxoSmithKline (GSK) is developing with U.S. partner Vir has indicated the drug is effective against the new Omicron variant, the British drugmaker said on Thursday.
Baca lebih lajut »
COVID-19 Antibody Drug Likely Works Against Omicron, Companies SayEarly lab studies show that a COVID-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology could be effective against the Omicron variant.
Baca lebih lajut »
U.K. Approves Covid Antibody Treatment That’s Likely Effective Against Omicron—Here’s What To KnowI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Baca lebih lajut »
UK Approves Covid Antibody Treatment That's Likely Effective Against Omicron—Here's What To KnowI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Baca lebih lajut »
Glaxo’s Covid-19 Antibody Drug Found to Be Effective Against OmicronThe antibody treatment was effective against the variant in early laboratory studies, setting it apart from similar therapies that appear to work less well against the highly mutated strain.
Baca lebih lajut »
Factbox: What COVID-19 vaccine and drug makers have to say about OmicronThe Omicron variant of the coronavirus has sparked fears that existing COVID-19 vaccines and treatment could be less effective against it.
Baca lebih lajut »